As tumor hypoxia is generally recognized as a contributor to immune resistance in the tumor microenvironment (42), it is conceivable that PD-L2 may potentially mediate immune resistance via promoting tumor hypoxia. Here, PDCD1LG2 is linked to neoplasm.